Sympathetic ophthalmia

Castiblanco, Claudia; Adelman, Ron A.

doi:10.1007/s00417-008-0939-8

Cited by 104 publications

(105 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Subsequently, the symptoms spread from the injured right lower extremity to the opposite lower extremity and finally to the upper extremities. Although this observation appears to be similar to the process of sympathetic ophthalmia, the pathophysiology of which is considered to involve a T cell mediated autoimmune response (18,19), the mechanism involved in the present case is unclear. It is possible that local muscle inflammation triggered by physical damage may have contributed to the development of cGVHD-related myositis in the present case.…”

Section: Discussionmentioning

confidence: 61%

Plasma Kinetics of Th1, Th2 and Th17 Cytokines in Polymyositis Related to Chronic Graft-versus-Host Disease

Koh

Nakashima

et al. 2016

Intern. Med.

View full text Add to dashboard Cite

We herein describe a case of myelodysplastic syndrome with chronic graft-versus-host disease (cGVHD)-related polymyositis. On approximately day 1,570 post HLA-identical sibling bone marrow transplant, the patient presented with a fever, myalgia and liver dysfunction. A muscle biopsy revealed destruction of the muscle fibers and infiltration of CD20 + B cells and CD4 + and CD8 + T cells, and a liver biopsy confirmed the findings of cGVHD. An analysis of plasma cytokine profiles indicated elevation of not only T-helper (Th)1 and Th2, but also Th17 cytokines. Increases in these cytokines in addition to the invasion of inflammatory cells might be associated with the pathophysiology of cGVHD involving the muscle and liver.

show abstract

Section: Discussionmentioning

confidence: 61%

Plasma Kinetics of Th1, Th2 and Th17 Cytokines in Polymyositis Related to Chronic Graft-versus-Host Disease

Koh

Nakashima

et al. 2016

Intern. Med.

View full text Add to dashboard Cite

show abstract

“…In der Literatur sind uneinheitliche Therapieschemata von 1 mg/kg Körpergewicht oraler Prednisolongabe bis zu initial 1000 mg intravenöser Verabreichung und langsamer Reduktion beschrieben [1,4,[6][7][8]. Eine langfristige Immunsuppression für insgesamt 6 bis 12 Monate wird empfohlen.…”

Section: Diskussionunclassified

Sympathische Ophthalmie

et al. 2016

View full text Add to dashboard Cite

This article describes the case of a 48-year-old male patient who presented with persistent inflammation and deterioration of vision to a best corrected visual acuity (BCVA) of 0.6 in the only functioning left eye. The right eye had suffered a severe penetrating ocular trauma 6 months prior to presentation. After diagnosis of a sympathetic ophthalmia a high dosage corticosteroid therapy was initiated. Due to intolerance with decompensating diabetes an immunosuppressive therapy with azathioprine was initiated. This therapy resulted in stable clinical findings with an increase in BCVA to 0.9.

show abstract

“…Demographic and clinical features of the cohort were otherwise similar to those reported in earlier series. 7 The authors cited previous reports of both CSF pleocytosis and meningeal symptoms in patients with SO and reminded us that such findings may be more common than generally appreciated. They also pointed out that the presence or absence of CSF pleocytosis and meningeal symptoms should not be used to distinguish between SO from VKH disease.…”

mentioning

confidence: 99%

“…Best-corrected vision at last visit was 20/40 or better in 11 patients (57.9%) and 20/200 or worse in 3 (15.8%), figures generally in line with previous clinic-based cohorts. 7 The authors concluded that SO can be controlled in virtually all patients with an aggressive, step-wise approach to corticosteroid-sparing immunosuppressive therapy, and that prolonged drugfree remission can be achieved in a minority of patients.…”

mentioning

confidence: 99%